メシル酸レンバチニB
メシル酸レンバチニB 物理性質
- 融点 :
- >220°C (dec.)
- 貯蔵温度 :
- -20°C Freezer
- 溶解性:
- DMSO(微量)、メタノール(微量)
- 外見 :
- 個体
- 色:
- ホワイトからオフホワイト
- InChIKey:
- HWLFIUUAYLEFCT-UHFFFAOYSA-N
- SMILES:
- O=C(N)C1C=C2C(N=CC=C2OC2C=C(Cl)C(NC(=O)NC3CC3)=CC=2)=CC=1OC.CS(=O)(O)=O
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
絵表示(GHS) |
|
注意喚起語 |
警告 |
危険有害性情報 |
コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
|
P264, P270, P301+P312, P330, P501 |
H315 |
皮膚刺激 |
皮膚腐食性/刺激性 |
2 |
警告 |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
H319 |
強い眼刺激 |
眼に対する重篤な損傷性/眼刺激 性 |
2A |
警告 |
|
P264, P280, P305+P351+P338,P337+P313P |
H335 |
呼吸器への刺激のおそれ |
特定標的臓器毒性、単回暴露; 気道刺激性 |
3 |
警告 |
|
|
|
注意書き |
P261 |
粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。 |
P305+P351+P338 |
眼に入った場合:水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。 |
|
メシル酸レンバチニB 価格
もっと(5)
メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01COBQV-5519 |
メシル酸レンバチニb
Lenvatinib mesylate |
857890-39-2 |
250mg |
¥39600 |
2018-12-26 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01COBQV-5519 |
メシル酸レンバチニb
Lenvatinib mesylate |
857890-39-2 |
1g |
¥97200 |
2018-12-26 |
購入 |
Sigma-Aldrich Japan
|
SML3017 |
≥98% (HPLC)
Lenvatinib mesylate ≥98% (HPLC) |
857890-39-2 |
10MG |
¥14800 |
2024-03-01 |
購入 |
Sigma-Aldrich Japan
|
SML3017 |
≥98% (HPLC)
Lenvatinib mesylate ≥98% (HPLC) |
857890-39-2 |
50MG |
¥59200 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01COBQV-5519 |
メシル酸レンバチニb
Lenvatinib mesylate |
857890-39-2 |
5g |
¥291600 |
2018-12-26 |
購入 |
メシル酸レンバチニB 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, 受容体チロシンキナーゼ阻害薬
商品名
レンビマ (エーザイ)
説明
Lenvatinib mesylate (lenvatinib) is an oral targeted therapy medicine known as a receptor‐type tyrosine kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily), which was developed at Eisai in 2015. It was approved by the FDA in 2015 for the treatment of differentiated thyroid cancer that is either locally recurrent, metastatic, or progressive and did not respond to radioactive iodine treatment. In May 2016, the FDA approved the drug as a combination therapy with everolimus for the treatment of advanced renal cell carcinoma. Because VEGF (and fibroblast growth factor receptors, known as FGFRs) are thought to play a role in cardiovascular signaling pathways, VEGF2R and FGFR inhibition are thought to be the mechanisms behind the primary side effect of lenvatinib mesylate, which is hypertension.
使用
Lenvatinib mesylate is used in cancer:(1) Endometrial carcinoma that is advanced and got worse after other systemic therapies. It is used with pembrolizumab in patients whose cancer is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) and cannot be treated with surgery or radiation therapy.(2) Hepatocellular carcinoma (a type of liver cancer). It is used as the first treatment in patients whose cancer cannot be removed by surgery.(3) Renal cell carcinoma (a type of kidney cancer) that is advanced(4)Thyroid cancer in certain patients whose cancer got worse, came back, or has spread to other parts of the body and did not respond to treatment with radioactive iodine.(5) Lenvatinib Mesylate is used in preparation of anti-human CTLA4xPD-1 bispecific antibodies for diagnosis, prevention and treatment of tumor or anemia.
Lenvatinib mesylate is also being studied in the treatment of other types of cancer.
定義
ChEBI: Lenvatinib mesylate is a methanesulfonate salt obtained by reaction of lenvatinib with one molar equivalent of methanesulfonic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine. It has a role as an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a fibroblast growth factor receptor antagonist, an orphan drug, a vascular endothelial growth factor receptor antagonist and an antineoplastic agent. It contains a lenvatinib(1+).
作用機序
Lenvatinib mesylate works by blocking proteins that signal cancer cells to multiply. It also blocks proteins that signal the formation of new blood vessels that are needed to support tumor growth. Blocking these signals keeps cancer cells from growing.
メシル酸レンバチニB 上流と下流の製品情報
原材料
準備製品
メシル酸レンバチニB 生産企業
Global( 355)Suppliers
857890-39-2(メシル酸レンバチニB)キーワード:
- 857890-39-2
- lenvatinib Methanesulfonate
- E7080 Mesylate
- 4-[3chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate
- lenvatinib Mesylate
- CAT#A863437
- Lenvatinib Mesylate,Amadis Chemical offer CAS#857890-39-2
- E7080;E-7080;E 7080
- maltitol E:candyli(at)speedgainpharma(dot)com
- LENVATINIB MESYLATE (E7080 MESYLATE)
- 4-[3-chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide mesylate
- lenvatinib Mesylate (E7080)
- 6-Quinolinecarboxamide,4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-,monomethanesulfonate
- envatinib MesyL
- lenvatinib Mesylate USP/EP/BP
- lenvatinib Mesylater
- 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide methanesulfonate
- Lenvatinib mesylateQ: What is
Lenvatinib mesylate Q: What is the CAS Number of
Lenvatinib mesylate
- 4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide monomethanesulfonate
- Lenvatinib mesilate
- Levaritinib mesylate
- Piperazine,5-(methylsulfonyl)-
- Lenvatinib Meylate
- Levatinib mesylate
- Lenvatinib Mesylat
- Lenvatinib mesylaye
- Levantinib mesylate
- Lenvatinib Mesylate (Form C and MIBK Solvate)
- 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide mesylate
- levitinib mesylate
- メシル酸レンバチニB
- レンバチニブメシル酸塩
- レンバチニブメシル酸塩 (JAN)